公开(公告)号：US10556948B2

公开(公告)日：2020-02-11

申请号：US15364612

申请日：2016-11-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Mohan Srinivasan ,  Shrikant Deshpande ,  Qihong Zhao ,  Huadong Sun ,  Ginger Rakestraw ,  Guodong Chen ,  Richard Y. Huang ,  Steven Sheriff ,  Cristian Rodriguez ,  John P. Throup ,  Rose A. Dibella

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/24 ,  A61K9/00 ,  C07K1/00 ,  A61K39/00

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

公开(公告)号：US11708405B2

公开(公告)日：2023-07-25

申请号：US16728757

申请日：2019-12-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Mohan Srinivasan ,  Shrikant Deshpande ,  Qihong Zhao ,  Huadong Sun ,  Ginger Rakestraw ,  Guodong Chen ,  Richard Y. Huang ,  Steven Sheriff ,  Cristian Rodriguez ,  John P. Throup ,  Rose A. Dibella

IPC: A61K39/395 ,  C07K16/24 ,  A61K47/68 ,  A61K9/00 ,  C07K16/00 ,  A61K39/00

CPC classification number: C07K16/24 ,  A61K9/0019 ,  A61K47/6845 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.